UTMD

Business Context and Reporting Period

Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: UTMD designs, manufactures, and markets proprietary, disposable medical devices primarily for hospital use in critical care, labor and delivery, and neonatal intensive care units (NICU). The company operates manufacturing facilities in Utah, Oregon, and Ireland. It competes on value-added technology and cost-effectiveness, selling through direct sales forces, independent distributors, and OEM channels.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales declined 1% to $26.95 million, driven by a 4% drop in international sales (specifically a 6% decline in blood pressure monitoring products) and a 2% decline in obstetrics sales. Domestic sales remained essentially flat.
• Profitability: Despite lower revenue, Net Income increased 10.4% to $5.93 million. This was driven by a record Gross Margin of 57.1% (up 150 basis points) and reduced operating expenses as a percentage of sales (22.7% vs. 24.9% in 2000).
• Debt Reduction: Long-term debt decreased significantly by $7.5 million (from $10.0 million to $2.5 million) as the company used operating cash flow to repay its line of credit.
• Share Count: Diluted shares outstanding decreased to 5.21 million from 5.98 million in 2000, contributing to a 27% increase in Diluted EPS.
• Product Mix: Sales of higher-margin domestic direct Ob/Gyn products increased, offsetting declines in lower-margin foreign blood pressure monitoring sales.

Guidance, Outlook, and Risks

Management Outlook

• 2002 Expectations: Management anticipates renewed top-line growth, record profitability margins, and the elimination of remaining bank debt. They expect operating margins to improve further due to the cessation of goodwill amortization under new FASB rules (SFAS 142).
• Strategic Initiatives: Plans include revitalizing the direct sales force, launching new products (PICC-Nate, OptiMicro needles), and actively seeking acquisitions to broaden the product platform.
• Patent Litigation: On January 16, 2002, a jury awarded UTMD $20 million in damages against Tyco/Kendallo LTP for patent infringement regarding the Intran Plus catheter. The company expects an appeal, with resolution likely by the end of 2003. This award is not included in 2001 financials.

Risks and Contingencies

• Competition: Pressure from Group Purchasing Organizations (GPOs) and large competitors offering lower-priced, less differentiated products.
• Regulatory: Dependence on FDA approvals for new products and compliance with international standards.
• Legal: Ongoing appeal of the patent infringement verdict; potential product liability claims (though historically low).
• Foreign Currency: Exposure to exchange rate fluctuations, particularly with the transition of Irish operations to the Euro in 2002.

Investor Verification Checklist

• Patent Verdict Status: Confirm the finality of the $20 million damages award against Tyco/Kendallo LTP and the likelihood of an injunction being granted.
• Debt Elimination: Verify the timeline for paying off the remaining $2.5 million line of credit in 2002.
• Goodwill Accounting: Review the impact of SFAS 142 on 2002 earnings, specifically the removal of the $569,000 annual goodwill amortization expense.
• International Sales Recovery: Monitor the performance of the Ireland subsidiary and foreign distributors to ensure the 2001 decline in blood pressure monitoring sales is reversed.
• Acquisition Activity: Assess any new acquisitions announced in 2002 and their accretive impact on earnings.